Oncolytics Biotech develops pelareorep, an experimental intravenous cancer therapy for gastrointestinal tumors. ONCY reports earnings on Wed, Nov 11, 2026. In the past 30 days there were 1 dark pool print.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 19 | HC Wainwright & Co. | Target lowered | Buy | |
| May 26 | HC Wainwright & Co. | Reiterated | Buy |
Seasonality
How ONCY has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in ONCY in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ONCY is in one of them and how their past ONCY trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ONCY in an article yet. Here's the latest on the wider market.
About Oncolytics Biotech
Oncolytics Biotech is a biopharmaceutical company based in San Diego, California. It is developing pelareorep, an experimental cancer therapy given intravenously that is made from a common virus that does not cause disease. The company is testing pelareorep alone and with other cancer treatments, mainly for gastrointestinal cancers, and plans to partner with larger drug companies. Its intended customers are cancer patients and the doctors who treat them.
- Headquarters
- San Diego, CA
- Founded
- 1998
- Website
- oncolyticsbiotech.com ↗